Merck的KEYTRUDA与化学治疗相结合,在高危病人中将宫颈癌死亡风险降低33%。 Merck's KEYTRUDA combined with chemoradiotherapy reduces cervical cancer death risk by 33% in high-risk patients.

Merck的KEYTRUDA(Pembrolizumab)与化学疗法(CRT)相结合,表明与当地新诊断出高风险子宫颈癌的病人单独接受CRT相比,死亡风险降低了33%。 Merck's KEYTRUDA (pembrolizumab) combined with chemoradiotherapy (CRT) has demonstrated a 33% reduction in the risk of death compared to CRT alone in patients with newly diagnosed high-risk locally advanced cervical cancer. 这一发现突显了KEYTRUDA作为有效治疗选择的潜力,显著提高了生存结果. This finding highlights the potential of KEYTRUDA as an effective treatment option for this patient population, enhancing survival outcomes significantly.